NDATOPICALGEL
Approved
Aug 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
MIRVASO (brimonidine tartrate) by Galderma is alpha-2 adrenergic agonist. Approved for ocular hypertension, open-angle glaucoma, glaucoma and 1 more indications. First approved in 2013.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRVASO is a topical brimonidine tartrate gel approved in 2013 for rosacea-associated erythema, functioning as an alpha-2 adrenergic agonist that reduces facial redness through direct vasoconstriction. The drug addresses multiple ophthalmic indications including glaucoma and ocular hypertension through dual mechanisms of reducing aqueous humor production and increasing uveoscleral outflow. Brimonidine tartrate is a well-established small molecule with a demonstrated safety profile across dermatology and ophthalmology.
$0.9MPart D
Peak5.1 years to LOEProduct is in peak lifecycle stage with modest Part D utilization, suggesting stable revenue but limited growth trajectory for commercial expansion.
Mechanism of Action
alpha-2 adrenergic agonist. Topical application of MIRVASO topical gel may reduce erythema through direct vasoconstriction.
Indications (4)
Worked on MIRVASO at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.